|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lloyd KL, Cree IA and Savage RS:
Prediction of resistance to chemotherapy in ovarian cancer: A
systematic review. BMC Cancer. 15:1172015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bast RC Jr, Hennessy B and Mills GB: The
biology of ovarian cancer: New opportunities for translation. Nat
Rev Cancer. 9:415–428. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Eckstein N, Servan K, Hildebrandt B,
Pölitz A, von Jonquières G, Wolf-Kümmeth S, Napierski I, Hamacher
A, Kassack MU, Budczies J, et al: Hyperactivation of the
insulin-like growth factor receptor I signaling pathway is an
essential event for cisplatin resistance of ovarian cancer cells.
Cancer Res. 69:2996–3003. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Eckstein N: Platinum resistance in breast
and ovarian cancer cell lines. J Exp Clin Cancer Res. 30:912011.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Miller DS, Blessing JA, Krasner CN, Mannel
RS, Hanjani P, Pearl ML, Waggoner SE and Boardman CH: Phase II
evaluation of pemetrexed in the treatment of recurrent or
persistent platinum-resistant ovarian or primary peritoneal
carcinoma: A study of the Gynecologic Oncology Group. J Clin Oncol.
27:2686–2691. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Aletti GD, Dowdy SC, Podratz KC and Cliby
WA: Relationship among surgical complexity, short-term morbidity,
and overall survival in primary surgery for advanced ovarian
cancer. Am J Obstet Gynecol. 197:676.e1–676.e7. 2007. View Article : Google Scholar
|
|
8
|
De Benedetti A and Graff JR: eIF-4E
expression and its role in malignancies and metastases. Oncogene.
23:3189–3199. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Polunovsky VA and Bitterman PB: The
cap-dependent translation apparatus integrates and amplifies cancer
pathways. RNA Biol. 3:10–17. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Clemens MJ: Targets and mechanisms for the
regulation of translation in malignant transformation. Oncogene.
23:3180–3188. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Larsson O, Li S, Issaenko OA, Avdulov S,
Peterson M, Smith K, Bitterman PB and Polunovsky VA: Eukaryotic
translation initiation factor 4E induced progression of primary
human mammary epithelial cells along the cancer pathway is
associated with targeted translational deregulation of oncogenic
drivers and inhibitors. Cancer Res. 67:6814–6824. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dong K, Wang R, Wang X, Lin F, Shen JJ,
Gao P and Zhang HZ: Tumor-specific RNAi targeting eIF4E suppresses
tumor growth, induces apoptosis and enhances cisplatin cytotoxicity
in human breast carcinoma cells. Breast Cancer Res Treat.
113:443–456. 2009. View Article : Google Scholar
|
|
13
|
Oridate N, Kim HJ, Xu X and Lotan R:
Growth inhibition of head and neck squamous carcinoma cells by
small interfering RNAs targeting eIF4E or cyclin D1 alone or
combined with cisplatin. Cancer Biol Ther. 4:318–323. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
De Benedetti A and Graff JR: eIF-4E
expression and its role in malignancies and metastases. Oncogene.
23:3189–3199. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Culjkovic B, Topisirovic I and Borden KL:
Controlling gene expression through RNA regulons: The role of the
eukaryotic translation initiation factor eIF4E. Cell Cycle.
6:65–69. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Topisirovic I, Siddiqui N, Orolicki S,
Skrabanek LA, Tremblay M, Hoang T and Borden KL: Stability of
eukaryotic translation initiation factor 4E mRNA is regulated by
HuR, and this activity is dysregulated in cancer. Mol Cell Biol.
29:1152–1162. 2009. View Article : Google Scholar :
|
|
17
|
Ko SY, Guo H, Barengo N and Naora H:
Inhibition of ovarian cancer growth by a tumor-targeting peptide
that binds eukaryotic translation initiation factor 4E. Clin Cancer
Res. 15:4336–4347. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Graff JR and Zimmer SG: Translational
control and metastatic progression: Enhanced activity of the mRNA
cap-binding protein eIF-4E selectively enhances translation of
metastasis-related mRNAs. Clin Exp Metastasis. 20:265–273. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li Y, Fan S, Koo J, Yue P, Chen ZG,
Owonikoko TK, Ramalingam SS, Khuri FR and Sun SY: Elevated
expression of eukaryotic translation initiation factor 4E is
associated with proliferation, invasion and acquired resistance to
erlotinib in lung cancer. Cancer Biol Ther. 13:272–280. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Graff JR, Konicek BW, Carter JH and
Marcusson EG: Targeting the eukaryotic translation initiation
factor 4E for cancer therapy. Cancer Res. 68:631–634. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yang SX, Hewitt SM, Steinberg SM, Liewehr
DJ and Swain SM: Expression levels of eIF4E, VEGF, and cyclin D1,
and correlation of eIF4E with VEGF and cyclin D1 in multi-tumor
tissue microarray. Oncol Rep. 17:281–287. 2007.PubMed/NCBI
|
|
22
|
Liang B, He Q, Zhong L, Wang S, Pan Z,
Wang T and Zhao Y: Circulating VEGF as a biomarker for diagnosis of
ovarian cancer: A systematic review and a meta-analysis. Onco
Targets Ther. 8:1075–1082. 2015.PubMed/NCBI
|
|
23
|
Solomon LA, Ali S, Banerjee S, Munkarah
AR, Morris RT and Sarkar FH: Sensitization of ovarian cancer cells
to cisplatin by genistein: The role of NF-kappaB. J Ovarian Res.
1:92008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wan J, Lata C, Santilli A, Green D, Roy S
and Santilli S: Supplemental oxygen reverses hypoxia-induced smooth
muscle cell proliferation by modulating HIF-alpha and VEGF levels
in a rabbit arteriovenous fistula model. Ann Vasc Surg. 28:725–736.
2014. View Article : Google Scholar :
|
|
25
|
Soni A, Akcakanat A, Singh G, Luyimbazi D,
Zheng Y, Kim D, Gonzalez-Angulo A and Meric-Bernstam F: eIF4E
knockdown decreases breast cancer cell growth without activating
Akt signaling. Mol Cancer Ther. 7:1782–1788. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Avdulov S, Li S, Michalek V, Burrichter D,
Peterson M, Perlman DM, Manivel JC, Sonenberg N, Yee D, Bitterman
PB, et al: Activation of translation complex eIF4F is essential for
the genesis and maintenance of the malignant phenotype in human
mammary epithelial cells. Cancer Cell. 5:553–563. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Castellvi J, Garcia A, Rojo F,
Ruiz-Marcellan C, Gil A, Baselga J and Ramon y Cajal S:
Phosphorylated 4E binding protein 1: A hallmark of cell signaling
that correlates with survival in ovarian cancer. Cancer.
107:1801–1811. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Meric F and Hunt KK: Translation
initiation in cancer: A novel target for therapy. Mol Cancer Ther.
1:971–979. 2002.PubMed/NCBI
|
|
29
|
Pinzaglia M, Montaldo C, Polinari D,
Simone M, La Teana A, Tripodi M, Mancone C, Londei P and Benelli D:
EIF6 over-expression increases the motility and invasiveness of
cancer cells by modulating the expression of a critical subset of
membrane-bound proteins. BMC Cancer. 15:1312015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Rhoads RE: Signal transduction pathways
that regulate eukaryotic protein synthesis. J Biol Chem.
274:30337–30340. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Brown EJ and Schreiber SL: A signaling
pathway to translational control. Cell. 86:517–520. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Metzger-Filho O, Moulin C and D'Hondt V:
First-line systemic treatment of ovarian cancer: A critical review
of available evidence and expectations for future directions. Curr
Opin Oncol. 22:513–520. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Agarwal R and Kaye SB: Ovarian cancer:
Strategies for overcoming resistance to chemotherapy. Nat Rev
Cancer. 3:502–516. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang Y, Han A, Chen E, Singh RK,
Chichester CO, Moore RG, Singh AP and Vorsa N: The cranberry
flavonoids PAC DP-9 and quercetin aglycone induce cytotoxicity and
cell cycle arrest and increase cisplatin sensitivity in ovarian
cancer cells. Int J Oncol. 46:1924–1934. 2015.PubMed/NCBI
|
|
35
|
Meng Q, Xia C, Fang J, Rojanasakul Y and
Jiang BH: Role of PI3K and AKT specific isoforms in ovarian cancer
cell migration, invasion and proliferation through the p70S6K1
pathway. Cell Signal. 18:2262–2271. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Arafa el-SA, Zhu Q, Barakat BM, Wani G,
Zhao Q, El-Mahdy MA and Wani AA: Tangeretin sensitizes
cisplatin-resistant human ovarian cancer cells through
downregulation of phosphoinositide 3-kinase/Akt signaling pathway.
Cancer Res. 69:8910–8917. 2009. View Article : Google Scholar
|
|
37
|
Johnson SW, Swiggard PA, Handel LM,
Brennan JM, Godwin AK, Ozols RF and Hamilton TC: Relationship
between platinum-DNA adduct formation and removal and cisplatin
cytotoxicity in cisplatin-sensitive and -resistant human ovarian
cancer cells. Cancer Res. 54:5911–5916. 1994.PubMed/NCBI
|
|
38
|
Zhou FF, Yan M, Guo GF, Wang F, Qiu HJ,
Zheng FM, Zhang Y, Liu Q, Zhu XF and Xia LP: Knockdown of eIF4E
suppresses cell growth and migration, enhances chemosensitivity and
correlates with increase in Bax/Bcl-2 ratio in triple-negative
breast cancer cells. Med Oncol. 28:1302–1307. 2011. View Article : Google Scholar
|
|
39
|
Bitterman PB and Polunovsky VA:
eIF4E-mediated translational control of cancer incidence. Biochim
Biophys Acta. 1849:774–780. 2015. View Article : Google Scholar
|
|
40
|
Chen L, Aktas BH, Wang Y, He X, Sahoo R,
Zhang N, Denoyelle S, Kabha E, Yang H, Freedman RY, et al: Tumor
suppression by small molecule inhibitors of translation initiation.
Oncotarget. 3:869–881. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Hoeffer CA, Cowansage KK, Arnold EC, Banko
JL, Moerke NJ, Rodriguez R, Schmidt EK, Klosi E, Chorev M, Lloyd
RE, et al: Inhibition of the interactions between eukaryotic
initiation factors 4E and 4G impairs long-term associative memory
consolidation but not reconsolidation. Proc Natl Acad Sci USA.
108:3383–3388. 2011. View Article : Google Scholar : PubMed/NCBI
|
